New candidate therapeutic agents for endometrial cancer

Potential for clinical practice (Review)

Kiyoko Umene, Kouji Banno, Iori Kisu, Megumi Yanokura, Yuya Nogami, Kosuke Tsuji, Kenta Masuda, Arisa Ueki, Yusuke Kobayashi, Wataru Yamagami, Eiichirou Tominaga, Nobuyuki Susumu, Daisuke Aoki

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Cases of endometrial cancer have increased in recent years, but the prognosis of patients with this disease has also been improved by combined modality therapy with surgery, radiotherapy and chemotherapy. However, the development of new therapy is required from the perspectives of conservation of fertility and efficacy for recurrent and intractable cancer. New candidate therapeutic agents for endometrial cancer include fourth-generation progestins for inhibition of growth and differentiation of endometrial glands; metformin for reduction of hTERT expression in the endometrium and inhibition of the mTOR pathway by activation of AMPK, with consequent inhibition of the cell cycle; mTOR inhibitors for supressing growth of cancer cells by G1 cell cycle arrest; microRNAs involved in the molecular mechanisms of oncogenesis and progression; and HDAC inhibitors that block the growth of cancer cells by transcriptional elevation of tumor-suppressor genes, cell cycle arrest and induction of apoptosis. In this study, we review the background and early clinical evidence for these agents as new therapeutic candidates for endometrial cancer.

Original languageEnglish
Pages (from-to)855-860
Number of pages6
JournalOncology Reports
Volume29
Issue number3
DOIs
Publication statusPublished - 2013 Mar

Fingerprint

Endometrial Neoplasms
G1 Phase Cell Cycle Checkpoints
Combined Modality Therapy
Neoplasms
Growth Inhibitors
AMP-Activated Protein Kinases
Histone Deacetylase Inhibitors
Metformin
Progestins
Growth
Endometrium
Cell Cycle Checkpoints
Tumor Suppressor Genes
MicroRNAs
Fertility
Cell Cycle
Carcinogenesis
Radiotherapy
Therapeutics
Apoptosis

Keywords

  • Endometrial cancer
  • Fourth-generation progestins
  • Metformin
  • MicroRNA
  • MTOR inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

New candidate therapeutic agents for endometrial cancer : Potential for clinical practice (Review). / Umene, Kiyoko; Banno, Kouji; Kisu, Iori; Yanokura, Megumi; Nogami, Yuya; Tsuji, Kosuke; Masuda, Kenta; Ueki, Arisa; Kobayashi, Yusuke; Yamagami, Wataru; Tominaga, Eiichirou; Susumu, Nobuyuki; Aoki, Daisuke.

In: Oncology Reports, Vol. 29, No. 3, 03.2013, p. 855-860.

Research output: Contribution to journalArticle

Umene, Kiyoko ; Banno, Kouji ; Kisu, Iori ; Yanokura, Megumi ; Nogami, Yuya ; Tsuji, Kosuke ; Masuda, Kenta ; Ueki, Arisa ; Kobayashi, Yusuke ; Yamagami, Wataru ; Tominaga, Eiichirou ; Susumu, Nobuyuki ; Aoki, Daisuke. / New candidate therapeutic agents for endometrial cancer : Potential for clinical practice (Review). In: Oncology Reports. 2013 ; Vol. 29, No. 3. pp. 855-860.
@article{6b274a8f454a4e56b0ff1470c2990963,
title = "New candidate therapeutic agents for endometrial cancer: Potential for clinical practice (Review)",
abstract = "Cases of endometrial cancer have increased in recent years, but the prognosis of patients with this disease has also been improved by combined modality therapy with surgery, radiotherapy and chemotherapy. However, the development of new therapy is required from the perspectives of conservation of fertility and efficacy for recurrent and intractable cancer. New candidate therapeutic agents for endometrial cancer include fourth-generation progestins for inhibition of growth and differentiation of endometrial glands; metformin for reduction of hTERT expression in the endometrium and inhibition of the mTOR pathway by activation of AMPK, with consequent inhibition of the cell cycle; mTOR inhibitors for supressing growth of cancer cells by G1 cell cycle arrest; microRNAs involved in the molecular mechanisms of oncogenesis and progression; and HDAC inhibitors that block the growth of cancer cells by transcriptional elevation of tumor-suppressor genes, cell cycle arrest and induction of apoptosis. In this study, we review the background and early clinical evidence for these agents as new therapeutic candidates for endometrial cancer.",
keywords = "Endometrial cancer, Fourth-generation progestins, Metformin, MicroRNA, MTOR inhibitors",
author = "Kiyoko Umene and Kouji Banno and Iori Kisu and Megumi Yanokura and Yuya Nogami and Kosuke Tsuji and Kenta Masuda and Arisa Ueki and Yusuke Kobayashi and Wataru Yamagami and Eiichirou Tominaga and Nobuyuki Susumu and Daisuke Aoki",
year = "2013",
month = "3",
doi = "10.3892/or.2013.2221",
language = "English",
volume = "29",
pages = "855--860",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - New candidate therapeutic agents for endometrial cancer

T2 - Potential for clinical practice (Review)

AU - Umene, Kiyoko

AU - Banno, Kouji

AU - Kisu, Iori

AU - Yanokura, Megumi

AU - Nogami, Yuya

AU - Tsuji, Kosuke

AU - Masuda, Kenta

AU - Ueki, Arisa

AU - Kobayashi, Yusuke

AU - Yamagami, Wataru

AU - Tominaga, Eiichirou

AU - Susumu, Nobuyuki

AU - Aoki, Daisuke

PY - 2013/3

Y1 - 2013/3

N2 - Cases of endometrial cancer have increased in recent years, but the prognosis of patients with this disease has also been improved by combined modality therapy with surgery, radiotherapy and chemotherapy. However, the development of new therapy is required from the perspectives of conservation of fertility and efficacy for recurrent and intractable cancer. New candidate therapeutic agents for endometrial cancer include fourth-generation progestins for inhibition of growth and differentiation of endometrial glands; metformin for reduction of hTERT expression in the endometrium and inhibition of the mTOR pathway by activation of AMPK, with consequent inhibition of the cell cycle; mTOR inhibitors for supressing growth of cancer cells by G1 cell cycle arrest; microRNAs involved in the molecular mechanisms of oncogenesis and progression; and HDAC inhibitors that block the growth of cancer cells by transcriptional elevation of tumor-suppressor genes, cell cycle arrest and induction of apoptosis. In this study, we review the background and early clinical evidence for these agents as new therapeutic candidates for endometrial cancer.

AB - Cases of endometrial cancer have increased in recent years, but the prognosis of patients with this disease has also been improved by combined modality therapy with surgery, radiotherapy and chemotherapy. However, the development of new therapy is required from the perspectives of conservation of fertility and efficacy for recurrent and intractable cancer. New candidate therapeutic agents for endometrial cancer include fourth-generation progestins for inhibition of growth and differentiation of endometrial glands; metformin for reduction of hTERT expression in the endometrium and inhibition of the mTOR pathway by activation of AMPK, with consequent inhibition of the cell cycle; mTOR inhibitors for supressing growth of cancer cells by G1 cell cycle arrest; microRNAs involved in the molecular mechanisms of oncogenesis and progression; and HDAC inhibitors that block the growth of cancer cells by transcriptional elevation of tumor-suppressor genes, cell cycle arrest and induction of apoptosis. In this study, we review the background and early clinical evidence for these agents as new therapeutic candidates for endometrial cancer.

KW - Endometrial cancer

KW - Fourth-generation progestins

KW - Metformin

KW - MicroRNA

KW - MTOR inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84872780227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872780227&partnerID=8YFLogxK

U2 - 10.3892/or.2013.2221

DO - 10.3892/or.2013.2221

M3 - Article

VL - 29

SP - 855

EP - 860

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 3

ER -